Mauna Kea Technologies announced the appointment of Sophie Baratte as Chief Commercial Officer. In this role, Ms. Baratte will coordinate the company's global marketing and business strategies and operations. Ms. Baratte has a strong medical device sales and marketing background with over 25 years of experience and multiple commercial successes at KCI LifeCell, CitoxLAB, Sorin Group, Johnson & Johnson and Beckman Coulter.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.434 EUR | +0.93% | +8.50% | -7.86% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-7.86% | 29.06M | |
-26.08% | 16.09B | |
-40.85% | 2.9B | |
+23.88% | 1.97B | |
-9.90% | 1.53B | |
+29.92% | 1.34B | |
-17.38% | 953M | |
-29.23% | 817M | |
+2.58% | 807M | |
-23.12% | 635M |
- Stock Market
- Equities
- ALMKT Stock
- News Mauna Kea Technologies
- Mauna Kea Technologies Appoints Sophie Baratte as Chief Commercial Officer